Brighton Jones LLC Increases Position in Eli Lilly and Company (NYSE:LLY)

Brighton Jones LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 6.3% in the 4th quarter, HoldingsChannel reports. The fund owned 9,674 shares of the company’s stock after acquiring an additional 577 shares during the period. Brighton Jones LLC’s holdings in Eli Lilly and Company were worth $5,639,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. JGP Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 0.9% in the fourth quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after buying an additional 16 shares during the period. Patton Albertson Miller Group LLC boosted its holdings in shares of Eli Lilly and Company by 2.8% during the third quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock worth $335,000 after purchasing an additional 17 shares during the period. Valley Wealth Managers Inc. grew its position in Eli Lilly and Company by 1.3% during the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after purchasing an additional 17 shares in the last quarter. Sandy Cove Advisors LLC increased its stake in Eli Lilly and Company by 0.8% in the 4th quarter. Sandy Cove Advisors LLC now owns 2,241 shares of the company’s stock valued at $1,307,000 after buying an additional 17 shares during the period. Finally, Lathrop Investment Management Corp lifted its position in Eli Lilly and Company by 1.2% in the 3rd quarter. Lathrop Investment Management Corp now owns 1,476 shares of the company’s stock worth $793,000 after buying an additional 18 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

NYSE:LLY traded up $44.36 during mid-day trading on Tuesday, reaching $781.56. 7,432,651 shares of the company were exchanged, compared to its average volume of 3,071,009. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The stock has a market cap of $742.61 billion, a PE ratio of 134.43, a PEG ratio of 1.60 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $392.26 and a 12 month high of $800.78. The company has a fifty day moving average of $760.89 and a 200 day moving average of $668.00.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.09 earnings per share. On average, research analysts anticipate that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.13% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

LLY has been the subject of several recent research reports. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Morgan Stanley upped their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Citigroup lifted their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. BMO Capital Markets increased their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Finally, JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $731.55.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.